Symbiotec Pharmalab IPO Gains Momentum as Investor Interest Surges for Growth-Oriented CDMO

Symbiotec Pharmalab IPO Gains Momentum as Investor Interest Surges for Growth-Oriented CDMO​

The initial public offering (IPO) of Symbiotec Pharmalab, a contract development and manufacturing organisation (CDMO) based in Madhya Pradesh, saw strong investor interest on the second day of bidding. The issue, priced within the range of Rs 938-988 per equity share, received 1.12 times subscription as of 10:50 am on August 25, according to NSE data.

The IPO holds a total size of Rs 1,757-crore, offering bids for 1,38,27,990 shares against the available 1,31,24,929 shares on offer. Institutional and retail investors showed solid demand, with Non-Institutional Investors (NIIs) subscribing at 1.37 times and the retail category registering a subscription of 1.2 times.

Grey Market Premium Signals Potential Listing Gains​

In unofficial market sentiment indicators, Symbiotec Pharmalab shares were noted to be commanding a grey market premium (GMP) of Rs 340. If priced at the upper end of the IPO range, this GMP suggests an estimated listing price of Rs 1,328 per share. This potential outcome translates into a projected listing gain of around 34.41 percent.

While GMP is an unofficial market indicator and does not guarantee actual returns or listing price, this sentiment indicates heightened investor expectation for the company. The IPO remains open for subscription until August 27.

Strategic Anchor Book and Fund Participation Details​

Ahead of the public issue, Symbiotec Pharmalab successfully raised Rs 526.2 crore through its anchor book allocation. This segment saw the allotment of 53.25 lakh equity shares to 34 anchor investors at Rs 988 apiece.

Major participants in the anchor round included Citigroup Global Markets, BNP Paribas, and Singularity AMC. Domestic mutual funds also contributed significantly, with eleven schemes picking up 31.98 lakh shares. This group included ICICI Prudential AMC, HDFC Mutual Fund, and Motilal Oswal AMC. Insurance companies like Tata AIA Life and Bajaj Life were among the participating anchor investors.

IPO Structure and Financial Trajectory​

The Symbiotec Pharmalab offering comprises a fresh issue worth Rs 150 crore and an Offer For Sale (OFS) amounting to Rs 1,607 crore. The OFS involves shares from Promoter Satwani Holdings and selling shareholders Rosewood Investments and Motilal Oswal.

Proceeds generated from the OFS will be distributed to the respective selling shareholders. Of the fresh issue funds, Rs 112.5 crore is earmarked for debt repayment, while the remaining amount is set aside for general corporate purposes.

Looking at the company’s financial outlook, Symbiotec Pharmalab projects significant growth. Profit is expected to rise at a compound annual growth rate (CAGR) of 4.81 percent between FY24 and FY26, reaching Rs 109.9 crore in FY26. Revenue is anticipated to increase at a CAGR of 10.16 percent over the same period, reaching Rs 869.1 crore.

Symbiotec Pharmalab’s Core Operations and Expansion Plans​

Symbiotec Pharmalab operates as a specialized CDMO, serving global specialty pharmaceutical and nutraceutical companies. Its operations are built across three key platforms: organic chemistry, biotechnology, and complex injectables.

The company currently possesses two operational industrial-scale API manufacturing facilities. These facilities boast a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and a fermentation capacity of 300 kilolitres (KL).

Demonstrating ambitious growth plans, the company has commissioned two additional manufacturing facilities in Ujjain and Mhow in Madhya Pradesh. Symbiotec is also expanding its biologics manufacturing capability and has proposed establishing a dedicated 14 KL fermentation facility at Ujjain.